Answers are grounded in this paper and cite their sources.
Invasive candidiasis (IC) remains the most common invasive mycosis world-wide, responsible for a wide range of infections that can range from superficial mucosal infections to life-threatening systemic diseases. Clinical trials of antifungal agents for IC are pivotal to its management. Therapeutic responses in these trials are currently based on consensus criteria initially presented by the Mycoses Study Group (MSG) and the European Organization for Research and the Treatment of Cancer (EORTC) in 2008. These 2008 definitions originally described by Segal et al are still employed by both investigators and regulatory agencies when evaluating antifungal drug efficacy and patient outcomes. However, advances in clinical mycology, the change in epidemiology of Candida infections due to the increase in non-albicans Candida species, and the increase in newer antifungal agents currently under development require a revision of these criteria to ensure appropriate and standardized adjudication of patient outcomes and to accurately capture responses to newer therapeutic regimens and modern interventions. Therefore, the European Confederation of Medical Mycology (ECMM) and Mycoses Study Group Education and Research Consortium (MSGERC) have decided to revise the criteria to be used for future studies.
No takes yet. Share an insight, caveat, or question.
Vázquez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: